The ideal in the biotech and pharma world may be for a company to
develop a strong internal R&D engine that regularly churns out
potential blockbuster compounds, but the reality is that most companies
have to turn to partnerships and acquisitions to manage risk and
maintain growth. Shire (NASDAQ: SHPG )
built itself into a significant biotech/pharma company on the basis of
strong internal CNS and rare disease R&D efforts, but has more
recently turned to M&A to improve its prospects. With Shire likely
to generate considerable cash flow in the coming years, the question
stands as to whether investors would be better-served with additional
M&A transactions or a reinvestment into its own internal R&D
capabilities.
Read the full article at The Motley Fool:
Will Shire PLC Build Or Buy Its Future?
No comments:
Post a Comment